肠道菌群
肠道微生物群
医学
微生物群
生物信息学
生物
计算生物学
免疫学
作者
Luana Alexandrescu,Alina Doina Nicoara,Doina Ecaterina Tofolean,Adelina Geanina Mocanu,Andreea Nelson‐Twakor,Cristina Tocia,Anamaria Trandafir,Andrei Dumitru,Eugen Dumitru,Cristian Florentin Aftenie,Ionela Preotesoiu,Elena Dina,Ioan Tiberiu Tofolean
摘要
Recent research indicates that the microbiome has a significant impact on the progression of inflammatory bowel disease (IBD) and that creating therapies that change its composition could positively impact the outcomes of IBD treatment. This review summarizes the results of extensive studies that examined IBD patients undergoing several therapies, including anti-TNF medication, vedolizumab, ustekinumab, probiotics, and fecal microbiota transplantation (FMT), and the alterations in their gut microbiota's composition and function. The objective was to investigate the variety and effectiveness of microbial species in order to discover new biomarkers or therapeutic targets that could improve the outcome of treatment for these patients. This research aimed to offer useful insights into personalized medicine techniques for managing IBD. Beneficial bacteria such as
科研通智能强力驱动
Strongly Powered by AbleSci AI